Table 1 Incidence and timing of hematologic malignancy onset in patients diagnosed with Immunotactoid glomerulonephropathy
Study/Case Report | Number of ITG patients included | Incidence of monoclonal spike | Incidence of hematologic malignancy | Onset of hematologic malignancy |
|---|---|---|---|---|
Pronovost et al. 1996 [11] | 22 | - | 9/22 | Not described |
Rosenstock JL et al., 2003 [7] | 6 | 4/6 | 2/6 | Before or concomitant to ITG diagnosis |
Bridoux et al., 2002 [2] | 14 | 5/14 | 7/14 | Before or concomitant to ITG diagnosis |
Nasr SH et al., 2012 [6] | 16 | 10/16 (63 %) | 6/16 (38 %) | Ranged from 6 years prior to concomitant diagnosis |
Fogo, A. et al., 1993 [12] | 6 | 3/6 | 1/6 | unclear |
Jacobson E et al., 2004 [10] | 1 | 1 | 1 | 8 months post-ITG diagnosis |
Jabur WL et al., 2008 [13] | 1 | 1 | 1 | concurrently |
Matsushita et al., 2005 [14] | 1 | 1 | 1 | 5 months prior to ITG |
Castro JE et al., 2012 [15] | 1 | 1 | 1 | 5 years prior to ITG |
Vigil et al., 1998 [16] | 1 | 1 | 1 | 5 months post-ITG diagnosis |
Witzens-Harig M et al., 2007 [17] | 1 | 1 | 1 | 3 years prior to ITG |